Our data now provide a strong rationale for targeting COX-2 expression in tumour-associated macrophages as a CRC chemoprevention strategy that is unlikely to share the cardiovascular toxicity associated with systemic pharmacological COX-2 inhibition8. Here, PTGS2 is linked to colorectal carcinoma.